Eton Pharmaceuticals Inc
NASDAQ:ETON
Gross Margin
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Gross Margin shows how much money a company keeps from each dollar of sales after paying for the products it sells. It tells how profitable the company`s core business is before other expenses.
Peer Comparison
| Country | Company | Market Cap |
Gross Margin |
||
|---|---|---|---|---|---|
| US |
|
Eton Pharmaceuticals Inc
NASDAQ:ETON
|
488.6m USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
959.3B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
585.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
291.8B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
238.2B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
242.2B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
305.1B USD |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.3T DKK |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
151.4B USD |
Loading...
|
|
| UK |
|
GSK plc
XETRA:GS71
|
103.6B EUR |
Loading...
|
Market Distribution
| Min | -24 813% |
| 30th Percentile | 28.9% |
| Median | 43% |
| 70th Percentile | 60.5% |
| Max | 10 905 714.3% |
Other Profitability Ratios
Eton Pharmaceuticals Inc
Glance View
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. The company is headquartered in Deer Park, Illinois and currently employs 17 full-time employees. The company went IPO on 2018-11-09. Eton is primarily focused on hospital injectable and pediatric rare disease products. The Company’s Biorphen product is an alpha-1 adrenergic receptor agonist indicated for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia. Its Alkindi Sprinkle product is a replacement therapy for pediatric adrenal insufficiency (AI), including congenital adrenal hyperplasia (CAH) in patients from birth to less than 17 years of age. Its product pipeline includes Zonisamide Oral liquid, Topiramate Oral Solution, Cysteine Injection, Dehydrated Alcohol Injection, Ephedrine Injection and Lamotrigine Oral Suspension. The firm's product candidates are primarily focused on two core areas: hospital-based products and pediatric oral liquid products.
See Also
Gross Margin is calculated by dividing the Gross Profit by the Revenue.
The current Gross Margin for Eton Pharmaceuticals Inc is 51.4%, which is below its 3-year median of 63.1%.
Over the last 3 years, Eton Pharmaceuticals Inc’s Gross Margin has decreased from 72.6% to 51.4%. During this period, it reached a low of 51.4% on Sep 30, 2025 and a high of 73.8% on Jun 30, 2023.
